Summit Therapeutics is focused on the discovery, development and commercialisation of novel medicines for diseases for which there are no existing or only inadequate therapies. Summit is currently advancing new therapies for the treatment of infectious diseases. Our goal is to become a fully integrated biopharmaceutical company.
Our clinical focus is currently on the infectious disease caused by Clostridium difficile bacteria.
Clostridium difficile infection, or CDI, is a serious illness and a major healthcare issue in hospitals, long-term care homes, and increasingly in the wider community. The key clinical issue with CDI is disease recurrence, with each additional episode of CDI being associated with greater disease severity, higher mortality rates and an increased burden on the healthcare system. We are developing ridinilazole (formerly SMT19969), a new mechanism antibiotic designed to selectively target C. difficile that has the potential to treat the initial infection and reduce rates of recurrent disease. Ridinilazole has demonstrated clinical proof of concept in a Phase 2 clinical trial and is expected to enter global Phase 3 trials in Q1 2019. The clinical and regulatory development of ridinilazole is being supported by an award from BARDA worth up to $62 million.
Summit is also advancing a pipeline of earlier stage new mechanism antibiotics. It is using its Discuva Platform to help discover and develop new antibiotics and recently unveiled two novel targets for the killing of the bacteria Neisseria gonorrhoeae.
Summit was founded in 2003 as a spin-out of the University of Oxford and our shares are listed on the AIM Market of the London Stock Exchange (symbol ‘SUMM’) and the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Oxfordshire, UK and have offices in Cambridge, Massachusetts, US and Cambridge, UK.